Nogova and colleagues recently performed a phase I trial assessing the efficacy of sorafenib and everolimus dual therapy in patients with KRAS-mutated NSCLC adenocarcinoma, using CT scans and FDG-PET scans [56]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.